Sunshine Lake Pharma Signs AI Drug R&D Framework with Shenzhen XtalPi

MT Newswires Live
01/27

Sunshine Lake Pharma (HKG:6887) said it has entered into a cooperation framework agreement with Shenzhen XtalPi Technology to pursue a joint venture focused on AI-driven drug research and development, according to a Monday Hong Kong bourse filing.

Shares of the pharmaceutical firm were up over 3% in Tuesday morning trade.

The parties plan to build an AI drug R&D platform, including a joint laboratory for innovative drug discovery, joint development of AI large models across the drug development lifecycle, and the creation of a "Model-as-a-Service" business model, the filing showed.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10